All data are based on the daily closing price as of March 28, 2025
s
Sunmax Biotechnology
4728.TWO
11.70 USD
-0.24
-2.01%
Overview
Last close
11.70 usd
Market cap
637.21M usd
52 week high
12.10 usd
52 week low
5.59 usd
Target price
N/A usd
Valuation
P/E
31.0497
Forward P/E
N/A
Price/Sales
12.1056
Price/Book Value
13.9502
Enterprise Value
627.64M usd
EV/Revenue
21.9469
EV/EBITDA
22.8619
Key financials
Revenue TTM
52.53M usd
Gross Profit TTM
43.05M usd
EBITDA TTM
29.44M usd
Earnings per Share
0.38 usd
Dividend
N/A usd
Total assets
56.44M usd
Net debt
N/A usd
About
Sunmax Biotechnology Co., Ltd., a biomedical company, develops, manufactures, and markets collagen-based medical devices in Taiwan and Mainland China. The company offers dermal fillers, including Sunmax FACIALGAIN collagen implant with lidocaine, Sunmax collagen implant I-Plus, Sumax collagen implant I, Sunmax FACIALGAIN collagen implant 1-Plus with lidocaine for the correction of facial defects, such as the fill up of wrinkles; and Porcogen, a sterile purified collagen solution for medical device, tissue engineering, and research purposes. It also provides Sunmax collagen dental bone graft, Sunmax collagen dental membrane, and Sunmax dental bone graft granules, which are used in the augmentation or reconstructive treatment of the alveolar ridge. In addition, the company offers Sunmax collagen bone graft matrix that provides a bone void filler that is resorbed and replaced with bone during the healing process; and skincare products comprising Sunmax 12 jiao didi spray, Sunmax 11 collagen moisturizing cream, and Sunmax collagen skincare that are used as aftercare of dermal filler treatment. Sunmax Biotechnology Co., Ltd. was founded in 2001 and is headquartered in Tainan City, Taiwan.